Drug intelligence / Profile preview

anti-IARS neutralizing antibody

Development stage
Preclinical
Lead developer
Zhejiang University
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Anti-IARS neutralizing antibody is an experimental monoclonal antibody that targets isoleucyl-tRNA synthetase (IARS), an enzyme traditionally involved in protein synthesis that has been found to have non-canonical pro-inflammatory roles in the skin. In the context of psoriasis, IARS is upregulated in epidermal keratinocytes and promotes inflammation via the Jak2/STAT3/CXCL16 signaling pathway. By binding to and neutralizing IARS, the antibody inhibits this pathway, leading to decreased expression of chemokines and cytokines such as IL-6, IL-1β, and S100A7. Preclinical research in imiquimod-induced psoriasiform mouse models has demonstrated that administration of these neutralizing antibodies can significantly reduce epidermal thickness and inflammatory cell infiltration, suggesting a potential new therapeutic strategy for treating psoriasis.

Other names
anti-IARS antibodyneutralizing anti-IARS antibody
02

Targets

IleRS (Isoleucyl-tRNA synthetase)

Beyond the preview

Go deeper on anti-IARS neutralizing antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-IARS neutralizing antibody.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call